Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction
Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
Heart failure (HF) is a severe cardiovascular disease with extremely high morbidity and mortality rates worldwide, and ischemic cardiomyopathy is an important cause of heart failure. Vericiguat is a soluble guanylate cyclase stimulator which has been verified to improve the cardiovascular outcomes in heart failure patients. The VICTORIA trial excluded patients with acute coronary syndrome in 3 months prior to the study start, so it is still unclear about the efficacy and safety of vericiguat in heart failure after acute myocardial infarction. So we conducted this multi-center, prospective, cohort study to estimate the efficacy and safety of vericiguat in HF patients after acute myocardial infarction.
Phase:
PHASE4
Details
Lead Sponsor:
Dongying Zhang
Collaborators:
The First Affiliated Hospital of Chongqing Medical Universty The Second Affiliated Hospital of Chongqing Medical University